Bob Ingram, vice chairman of pharmaceuticals for GlaxoSmithKline (GSK), will discuss today’s business environment and the pharmaceutical industry during a question-and-answer session at 4:30 p.m., Wednesday, Oct. 19 in Yeager Recital Hall on the Elon University campus.
Ingram’s visit is part of the Legends of Business program, sponsored by the Martha and Spencer Love School of Business at Elon. The program gives students the opportunity to interact with experienced and influential corporate and business leaders.
Ingram is the former CEO of GlaxoWellcome and played an important role in the 2000 merger of GlaxoWellcome and SmithKlineBeecham to form GSK, the world’s second-largest pharmaceutical company. As vice chairman of pharmaceuticals, Ingram represents GSK as a member of the executive committee and board of the Pharmaceutical Research and Manufacturers Association.
He began his career as a pharmaceutical sales representative, advancing to leadership roles with Merck & Co. and Merrill Dow Pharmaceuticals before joining GlaxoWellcome in 1990.
Ingram serves on the board of directors of Wachovia Corp., Nortel Networks, Lowe’s Companies, Allergan, Edwards Lifesciences Corp., and Valeant Pharmaceuticals International. He is chairman of OSI Pharmaceuticals, Inc.
A dedicated community volunteer, Ingram serves as chairman of the board of trustees of the American Cancer Society Foundation, and was asked by former President George Bush to form and chair the CEO Roundtable on Cancer. He serves on the boards of the H. Lee Moffitt Cancer Center and Research Institute and the James B. Hunt Jr. Institute for Educational Leadership and Policy. In 2004, Ingram received the Martin Luther King Jr. Legacy Award in recognition of his national and international service on behalf of GSK.
-30-